BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 23892527)

  • 1. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.
    Pan K; Li YQ; Wang W; Xu L; Zhang YJ; Zheng HX; Zhao JJ; Qiu HJ; Weng DS; Li JJ; Wang QJ; Huang LX; He J; Chen SP; Ke ML; Wu PH; Chen MS; Li SP; Xia JC; Zeng YX
    Ann Surg Oncol; 2013 Dec; 20(13):4305-11. PubMed ID: 23892527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.
    Hui D; Qiang L; Jian W; Ti Z; Da-Lu K
    Dig Liver Dis; 2009 Jan; 41(1):36-41. PubMed ID: 18818130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
    Pan QZ; Wang QJ; Dan JQ; Pan K; Li YQ; Zhang YJ; Zhao JJ; Weng DS; Tang Y; Huang LX; He J; Chen SP; Ke ML; Chen MS; Wicha MS; Chang AE; Zeng YX; Li Q; Xia JC
    Sci Rep; 2015 Mar; 5():9202. PubMed ID: 25776856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.
    Huang ZM; Li W; Li S; Gao F; Zhou QM; Wu FM; He N; Pan CC; Xia JC; Wu PH; Zhao M
    J Immunother; 2013 Jun; 36(5):287-93. PubMed ID: 23719239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.
    Pan QZ; Liu Q; Zhou YQ; Zhao JJ; Wang QJ; Li YQ; Tang Y; Gu JM; He J; Chen SP; Weng DS; Xia JC
    Cancer Immunol Immunother; 2020 May; 69(5):825-834. PubMed ID: 32060687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
    Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
    Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant cytokine-induced killer cells with minimally invasive therapies augmented therapeutic efficacy of unresectable hepatocellular carcinoma.
    Huang ZM; Lai CX; Zuo MX; An C; Wang XC; Huang JH; Ning E
    J Cancer Res Ther; 2020; 16(7):1603-1610. PubMed ID: 33565506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma].
    Zhou QM; Wu PH; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 Nov; 25(11):1414-8. PubMed ID: 17094912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection.
    Chen JL; Lao XM; Lin XJ; Xu L; Cui BK; Wang J; Lin GH; Shuang ZY; Mao YZ; Huang X; Yun JP; Jin JT; Li SP
    Medicine (Baltimore); 2016 Feb; 95(5):e2665. PubMed ID: 26844496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis.
    Yu R; Yang B; Chi X; Cai L; Liu C; Yang L; Wang X; He P; Lu X
    Drug Des Devel Ther; 2017; 11():851-864. PubMed ID: 28360510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
    Chang B; Shen L; Wang K; Jin J; Huang T; Chen Q; Li W; Wu P
    Liver Int; 2018 Aug; 38(8):1449-1458. PubMed ID: 29356308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.
    Cui J; Wang N; Zhao H; Jin H; Wang G; Niu C; Terunuma H; He H; Li W
    Int J Cancer; 2014 Jan; 134(2):342-51. PubMed ID: 23825037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer.
    Zhu Y; Zhang H; Li Y; Bai J; Liu L; Liu Y; Qu Y; Qu X
    Cancer Immunol Immunother; 2013 Oct; 62(10):1629-35. PubMed ID: 23974720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Cancer Immunol Immunother; 2019 Jan; 68(1):23-32. PubMed ID: 30232520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma.
    Zhan HL; Gao X; Pu XY; Li W; Li ZJ; Zhou XF; Qiu JG
    Chin Med J (Engl); 2012 Nov; 125(21):3771-7. PubMed ID: 23106871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas.
    Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC
    J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of CIK in the treatment of TACE combined with RFA for HCC in long-term survival and prognostic analysis].
    Wang JP; Li W; Huang ZL; Wu PH; Li XS; Wei YD; Zhou QM; Pan CC; Xia JC; Zhao M
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(43):3062-6. PubMed ID: 23328379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative combined with postoperative chemoembolization can improve survival in patients with hepatocellular carcinoma: a single-center study.
    Liu Y; Yang R
    J Vasc Interv Radiol; 2009 Apr; 20(4):472-83. PubMed ID: 19250841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
    Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH
    Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.